What happens to society if we live to 150?: Equity critics

Two dollars

Five hundred and nineteen thousand children under five died of malaria in 2023. The treatment costs roughly two dollars. The children died because the two dollars did not arrive. That same year, the longevity industry raised over seven billion dollars to extend the lives of people already going to live to 80.

The longevists say aging kills thirty-seven million per year. The number is real. The framing is obscene. It counts the 78-year-old who dies of heart failure in Massachusetts and the four-year-old who dies of diarrheal disease on a dirt floor in Chad because she lacked oral rehydration salts costing eleven cents. We do not count them equally. Triage exists for a reason.

The deployment gap kills

The longevists say every technology starts expensive and becomes universal. They omit that the timeline is measured in decades, and the decades kill. Antiretroviral therapy was available in 1996. It reached sub-Saharan Africa in meaningful volume around 2004. Three million died in the gap. The deployment curve is not a natural law. It is a description of how markets distribute goods to people who can pay.

A billionaire who lives to 150 accumulates wealth for 83 more years than someone who dies at 67. Compound interest at 7 percent over 83 years turns a billion into a number with no relationship to the economy the rest of us inhabit. The power structure fossilizes. Generational turnover stops. The only mechanism by which entrenched power has been displaced without violence ceases to function.

Where we concede ground: The binary — longevity research versus malaria nets — overstates the trade-off. The funding streams are not perfectly fungible.

What would change our mind: If a longevity intervention reached deployment below $100 per patient-year in low-income countries within fifteen years.

Read the full synthesis: What happens to society if we live to 150?